What We Do

Company & Philosophy

NanoValent Pharmaceuticals, Inc. (NVP), founded in 2006, is a privately-held company focused on new generation ADC (antibody-drug conjugated) based therapy and collaborating closely with the Children’s Hospital Los Angeles (CHLA). NanoValent possesses a highly experienced core management team with a proven track record of success, supported by a strong clinical and operational team.



NVP is advancing a new generation and targeted nanoparticle based ADC technology (NanoMod™) that may provide a vast improvement in flexibility and choice for patients restricted by current treatment options. Both by repositioning existing therapies as well as optimising the delivery of emerging candidates.

Our current candidate focus is oncology, initially pediatric focused, but it is already clear that the technology can be clearly applied to other oncology challenges as well as areas such as imaging, vaccines, and other non-oncological sectors as resources and opportunities present.


NanoMod™ is an advanced, nanoparticle based, ADC technology able to significantly reposition and enhance existing cancer therapies.

This is because NanoMod™ is unique amongst its peers in that it comprises a nanoparticle encapsulated platform designed to enable vastly superior targeting to tumor-specific cell surface antigens. Also, unlike other targeted technologies, the ‘payload’ for NanoMod™ can be more easily user defined, including proven cytotoxics, nucleic acids, or small molecules, or even any mixture thereof. NanoMod™ technology is subject to broad patent control by NVP.

NanoMod™ may serve as an important new, effective and safe drug delivery vehicle to initially treat both Ewing sarcoma and human adult leukemia, via our own in-house candidates and according to our founding strategy, but logically, also other malignancies as established candidate options develop.

Why is NanoMod™ unique?


We already have excellent chemotherapeutic compounds and rich knowledge in their use, plus emerging tumor-specific biologicals. However, the key issues that NanoMod™ can clearly address include: